See veebileht kasutab küpsiseid kasutaja sessiooni andmete hoidmiseks. Veebilehe kasutamisega nõustute ETISe kasutustingimustega. Loe rohkem
Olen nõus
"Muu" projekt MP1GV12123
MP1GV12123 "Tüüp 2 diabeedi genoomne, metaboloomne ja demograafiline iseloomustus Eesti elanikkonnas (1.05.2012−30.04.2013)", Andres Metspalu, Tartu Ülikool.
MP1GV12123
Tüüp 2 diabeedi genoomne, metaboloomne ja demograafiline iseloomustus Eesti elanikkonnas
Genomic, metabolic and demographic characteristics of type 2 diabetes in the Estonian population
1.05.2012
30.04.2013
Teadus- ja arendusprojekt
Muu
ValdkondAlamvaldkondCERCS erialaFrascati Manual’i erialaProtsent
1. Bio- ja keskkonnateadused1.3. GeneetikaB220 Geneetika, tsütogeneetika 1.5. Bioteadused (bioloogia, botaanika, bakterioloogia, mikrobioloogia, zooloogia, entomoloogia, geneetika, biokeemia, biofüüsika jt50,0
3. Terviseuuringud3.7. Kliiniline meditsiinB640 Neuroloogia, neuropsühholoogia, neurofüsioloogia 3.2. Kliiniline meditsiin (anestesioloogia, pediaatria, sünnitusabi ja günekoloogia, sisehaigused, kirurgia, stomatoloogia, neuroloogia, psühhiaatria, radioloogia, terapeutika, otorinolarüngoloogia, oftalmoloogia)50,0
AsutusRollPeriood
Tartu Ülikoolkoordinaator01.05.2012−30.04.2013
AsutusRiikTüüp
European Foundation for the Study of Diabetes
PerioodSumma
01.05.2012−30.04.2013100 000,00 EUR
100 000,00 EUR
0,00 EUR

The main goal of the project is to investigate the epidemiology of type 2 diabetes mellitus in the Estonian population by combining the detailed phenotype and disease information of the population-based database (representing 5% of the Estonian population, including 2092 type 2 diabetes patients) of the Estonian Genome Center of the University of Tartu (EGCUT) with genomics and metabolomics data.This population-based biobank offers unique opportunities to conduct the research in a nation-wide framework. The epidemiological characterization of the type 2 diabetes in the Estonian population is achieved by studying the distribution of the disease across gender, age, and other demographic groups. Thegenome-wide association study (GWAS) for fasting hyperglycemia will allow to determine the extent to which the genomic markers or their combinations with the phenotypic markers are indicative of inclination to the T2DM. This can lead to determination of the role of genetic parameters relative to the environmental ones in developing the T2DM. Combining the genome-wide and metabolomics association studies defines one of the main novel aspects of our approach. We are utilizing this powerful amalgamate of genomics and metabolomics thanks to our collaboration with the University of Oulu. Their NMR based method for determination of metabolite concentrations from blood serum allows deep phenotyping – a preferred method for obtaining phenotypes for exact studies. Ultimately, we aim to provide basic scientific and public health knowledge about the T2DM in Estonia, validate the known loci, and discover novel candidates for pathogenetic mechanisms.
The main goal of the project is to investigate the epidemiology of type 2 diabetes mellitus in the Estonian population by combining the detailed phenotype and disease information of the population-based database (representing 5% of the Estonian population, including 2092 type 2 diabetes patients) of the Estonian Genome Center of the University of Tartu (EGCUT) with genomics and metabolomics data.This population-based biobank offers unique opportunities to conduct the research in a nation-wide framework. The epidemiological characterization of the type 2 diabetes in the Estonian population is achieved by studying the distribution of the disease across gender, age, and other demographic groups. Thegenome-wide association study (GWAS) for fasting hyperglycemia will allow to determine the extent to which the genomic markers or their combinations with the phenotypic markers are indicative of inclination to the T2DM. This can lead to determination of the role of genetic parameters relative to the environmental ones in developing the T2DM. Combining the genome-wide and metabolomics association studies defines one of the main novel aspects of our approach. We are utilizing this powerful amalgamate of genomics and metabolomics thanks to our collaboration with the University of Oulu. Their NMR based method for determination of metabolite concentrations from blood serum allows deep phenotyping – a preferred method for obtaining phenotypes for exact studies. Ultimately, we aim to provide basic scientific and public health knowledge about the T2DM in Estonia, validate the known loci, and discover novel candidates for pathogenetic mechanisms.
TegevusProtsent
Alusuuring60,0
Rakendusuuring40,0